447 results about "Autoantibody" patented technology

Methods are provided for monitoring treatment of a subject using heparin therapy or a ligand, such as an CD20 or CD52 antibody, that binds to a cellular marker and to which the subject may develop masking reactions or auto-antibodies that inhibit evaluation of treatment. The methods involve adding to a single container a sample containing cells that express the cellular target with (i) a soluble ligand that binds the cellular target, (ii) a soluble ligand that binds the soluble analyte or a competing soluble analyte; and (iii) a capture medium that binds directly to the soluble analyte, indirectly to the soluble analyte, or to the soluble ligand that binds to the soluble analyte. Complexes formed in the container by interaction of these components are substantially simultaneously analyzed and quantitated without physically separating the complexes. Kits for performing the assays are also provided.

The present invention comprises methods and compositions for detecting cancer in an individual comprising autoantibodies to cancer-associated antigens. Specifically, the present invention comprises methods and compositions for detecting autoantibodies to cancer-associated antigen in a bodily fluid as well as use of said autoantibodies as a means to detect the presence of cancer-associated antigens.

The invention discloses a detection method of an aquaporin-4 autoantibody, a fusion expression virus vector and application thereof. The virus vector is pCDH-MCS-AQP4-EF1-copGFP, the nucleotide sequence of which is shown as a sequence table SEQIDNO.2. The invention further discloses application of the fusion expression virus vector in improving the clinical diagnosis and treatment level of ophthalmoneuromyelitis and multiple sclerosis. By adopting immunofluorescent cytochemical staining with higher sensitivity and specificity combined with a flow cytometric detection technology, the AQP-4 antibody is quantitively and qualitatively detection clinically, so that the detection result is more stable, and the labor and the time cost are extremely saved. The project is established to extremely improve the diagnosis and treatment level of ophthalmoneuromyelitis and multiple sclerosis, so that the labor capacity and the living quality of the patient are improved, and huge social and economic benefits are generated.

ITP may be treated using a method that involves identifying the autoimmune response, collecting allogeneic platelets, sterilizing allogeneic platelets and feeding them orally. Auto-antigens contained on the surface of allogeneic platelets administered to the intestines deactivate or delete lymphocytes responsible for auto-antibody production. This treatment can be used for ITP, specifically targets the cause of the disease and provides the possibility of a sustained response without further medication.

Methods for detecting or capturing low-avidity autoantibodies in a biological sample are provided. Target antigen used to assay for the low-avidity autoantibodies of interest is immobilized on a solid phase. The biological sample is contacted under low conductivity condition with the target antigen for which the autoantibodies has specific binding affinity. Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest.

The present invention relates to novel methods and kits for monitoring the therapeutic inactivating capacity of a subject. Moreover, the present invention further relates to methods and kits for determining and / or monitoring a therapeutic protocol for a subject afflicted with auto antibodies specific for a natural substance, wherein these auto antibodies develop as a result of therapeutic administration of the natural substance or an analog thereof. These methods and kits can be used, for example, to initiate, terminate, or adjust the level of administration of any of a variety of therapeutic agents.

The present invention provides assays for detecting and measuring the presence or level of autoantibodies to anti-TNFα drug therapeutics in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and / or reducing toxicity in subjects receiving anti-TNFα drugs for the treatment of TNFα-mediated disease or disorders.

The invention provides a kit for detecting an Alzheimer autoantibody in serum. The kit comprises an antigen protein combination, the antigen protein combination contains at least four proteins, and the proteins are selected from RABPT5, RAGE, CRYAB, SRPK1, MAPT, MBP, PLP1, PTCD2, FRMD8, POMC, DNAJC8, CENTA2, HSP60, ADARB1, ASXL1, EDRK, GDF11, P21, CCL2, IL18, VEGF, LENG1 and MRPL34. The inventionfurther provides application of the limited antigen protein combination to preparation of a reagent for detection, diagnosis or risk prediction of Alzheimer, and methods for detection, diagnosis or risk prediction of Alzheimer.

The present invention provides a method for detecting autoantibodies in a subject which reacts with a GP73 antigen. Increased levels of GP73-specific autoantibodies in a sample from the subject which bind to GP73 antigen are indicative of liver disease in the subject.

The invention discloses five categories of denaturizing allosteric cyclic citrulline polypeptide, fusion protein, antibodies and a kit thereof, which are formed by synthesizing related antigens that antibodies of rheumatoid arthritis patients can specifically recognize, independent designing amino acid sequences and structures with special derivations, and tests prove that the invention can combine with antibodies in RA blood serum and have better immunity reaction compared with the existing cyclic citrulline polypeptide detections, such as CCP and the like. The polypeptides carry out denaturizing and allosteric design and synthesis according to metabolism of arginine residues, and compared with projects of CCP, C-CRP and RF and the like, the five categories of denaturizing allosteric cyclic citrulline polypeptides are characterized by good specificity, high relevance ratio and high primitive diagnosis rate, etc.

The invention provides a human body anti-AQP4 autoantibodies detection material and a preparation method thereof. The preparation method comprises the steps of firstly acquiring M1 and M23 subtype AQP4 overall length target genes, dyeing into an HEK293 cell, and building an HEK293 / pCI-neo-M1-AQP4 cell and an HEK293 / pCI-neo-M23-AQP4 cell expressing M1 and M23 subtype AQP4; extracting an AQP4-cell membrane complex of the cells; finally curing the AQP4-cell membrane complex on a carrier, and obtaining the human body anti-AQP4 autoantibodies detection material. According to the human body anti-AQP4 autoantibodies detection material and the preparation method thereof provided by the invention, the extracted AQP4-cell membrane complex is used as a detection material, so that the intrinsic protein amount causing background coloration can be reduced; compared with a method for using the cell as the detection material for carrying out immunofluorescence detection, the detection sensitivity and the specificity are further increased, a detection result is easier and clear to judge, and the AQP4 autoantibodies of a patient can be simply, conveniently and quickly detected.

Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).

The invention relates to a biomarker related to a tumor immunotherapy effect and an application thereof, and discloses a biomarker for predicting the tumor immunotherapy effect, and the biomarker is an autoantibody of a group of tumor-associated antigens. The biomarker can be detected in a sample from a tumor patient to predict the clinical effect of administration of immunotherapy, thereby facilitating the determining of whether the tumor patient can benefit from immunotherapy. The invention also provides an antigen protein combination for detecting the biomarker, a kit containing the antigenprotein combination, and a corresponding detection or diagnosis method.

A chemical luminous ligand analysis method for quantitatively checking human antibodies belongs to the biomedical technical field, which comprises: using the generality that staphylococcal protein A (SPA) can react with Fc point of IgG in mice; using the monoclonal antibody of high affinity and specificity to prepare a standard product to establish a standard curve; respectively reacting the monoclonal antibody and the antibody in the sample with enzyme-labeled antigens; using the nanometer magnetic particles coated by SPA as ligand to separate solid and liquid; and using enzymatic chemical illumination reaction catalyzed by horseradish peroxidase (HRP) to process illumination check; thereby establishing a chemical luminous ligand quantitative analysis on human antibodies. The chemical luminous ligand analysis method is suitable for quantitatively checking all human antibodies, for resolving the problem of prior art while most human antibodies can not be accurately and quantitatively checked, avoiding cross reaction and avoiding false negative result or false positive result.

The present invention relates to unglycosylated isolated and purified recombinant polypeptides comprising a fusion protein able to bind to autoantibodies produced in response to an autoimmune disease associated with an immune reaction to a TSH-receptor (TSHR). Also disclosed are methods of detecting and / or quantifying such autoantibodies using the isolated and purified recombinant polypeptides and respective kits.

Methods, kits, arrays, and biosensors for detecting proteins, modified-proteins, protein-protein interactions, protein-DNA interactions, autoantibodies, and protein-small molecule interactions, are disclosed. A representative method of detecting proteins of the present invention includes exposing a solid support to a solution containing proteins; conjugating proteins to the solid support; exposing the solide support to a plurality of types of DNA-conjugated antibodies, wherein each type of DNA-conjugated antibody has an affinity for a specified protein; forming a complex between a protein conjugated with the solid support and a type of DNA-conjugated antibody when the protein is the specified protein for which the DNA-conjugated antibody has an affinity; separating the complex from the solution of proteins and the DNA-conjugated antibodies; releasing DNA from the DNA-conjugated antibodies; and detecting the DNA, wherein each DNA indicates the presence of the specified proteins.

The invention provides a chemiluminescent immunoassay kit for thyroid peroxidase autoantibodies and a preparation method thereof. The invention has the advantages that the reaction pattern of the double antigen sandwich method is adopted, the chemiluminescent technology and the biotin-avidin immune amplifying technological principle are effectively utilized, horse radish peroxidase is adopted to be as the marker enzyme, the content of the thyroid peroxidase autoantibodies in human serum samples is quantitatively detected, and the detection sensitivity can be ensured. The kit of the invention has the advantages of high sensitivity, good repeatability, good stability and high detection efficiency, and can provide a timely and reliable experimental basis for the clinical diagnosis and the treatment of thyroid disorders.

A method for screening a substance that inhibits the onset of anti-cardiac troponin I autoantibody-related disease, a pharmaceutical composition and a base material for therapy of cardiac disease that contains the substance obtained by aforesaid method thereof, a therapeutic apparatus that removes anti-troponin I autoantibody for aforesaid antibody related disease, a method of making an animal model for evaluating cardiac disease characterized by administrating anti-cardiac troponin I antibody, a method of selection of a therapeutic substance for cardiac disease characterized by using aforesaid animals, and a diagnosis of dilated cardiomyopathy characterized by measuring anti-cardiac troponin I autoantibody. An apparatus of the present invention that removes anti-cardiac troponin I antibody and a pharmaceutical composition for therapy of the antibody related disease may be useful for a therapy and / or prevention of cardiac disease.

The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and / or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.

The invention relates to a test reagent box of multiple antigen membrane method which is used for diagnosing RA, it includes tablets and response groove, the tablets hold on the response groove; the tablets gap corresponding to the response groove gap; there is multi-personal reaction zone on the tablets which correspond with the multi-groove of reaction groove, there is a gap on the top of each groove; membrane bar test paper adhere to each reaction zone and with RA correlate antigen and response control belt; the RA related antigen is the corresponding antigen of RF, anti-CCP, anti-RA-33 antibody, anti-Sa antibody, anti-P68 or more than four kinds of antigen in antigen epitope polypeptide or antigen epitope polypeptide, the response control belt is a mixture of man IgG and man IgM. The reagent box in this invention overcome the lack of detection sensitivity and Specificity of the single autoantibody and the red tape of several autoantibody detection in a single operation, it provide the accuracy and convenience of RA diagnosis. The invention also disclosed the method of how to make the test box.

The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and / or monitoring of treatment regimens.

There are provided peptides derived from antibodies with reactivity against a GPI linkage epitope and functionally equivalent ligands. These peptides can be used in the therapy and diagnosis of a variety of diseases, all of which are considered to be caused by the inappropriate presence in the body of autoantibodies which are reactive with GPI linkage epitopes. There is also described a mechanism of action of these autoantibodies which compromises the organism, so causing disease, and a method of prevention of disease and detection of the autoantibody.

A method and kit for screening a sample of body fluid for at least one autoantibody to at least one antigen. A source of at least one antigen to the autoantibody is provided. A substrate having immobilized thereto at least one antibody to the antigen is also provided. The antigen source is contacted with the sample of body fluid, so as to obtain a mixture wherein the antigen is allowed to substantially bind with the autoantibody, when the latter is present in the sample of body fluid. The mixture is allowed to flow relative to the substrate so as to allow the mixture to contact the antibody immobilized to the substrate. Labeling means are provided to permit monitoring of binding of the autoanitbody and the antigen present in the mixture, so as to provide an indication of the presence of the autoanitbody in the sample of body fluid.

Disclosed are methods and materials providing fluorescence detection of autoantibodies present in individuals who have developed or are at risk for type 1 diabetes. Provided is a plasmonic chip capable of fluorescence-enhancement of >100-fold. The fluorescent signal is generated by an anti-human antibody antibody, such as an anti-IgG antibody that is coupled to a fluorophore selected to emit at a wavelength enhanced by the plasmonic chip, for example in the NIR.

The present invention relates to a rheumatoid arthritis autoantibody conjugated antigen and applications thereof. The present invention discloses a novel detection antigen of rheumatoid arthritis antibody, wherein particularly the detection antigen can be used as the RA diagnosis and early diagnosis indicator, and is superior to the clinically developed detections of CCP, CRP, IgG-RF, IgM-RF and the like, such that the detection antigen can be used as the valuable reference indicator for clinical early treatment or prevention of RA, and can further be used as the RA pathogenesis development indicator.

The invention relates to a set of a kit for detecting specificity platelet antoantibody by the combination of monoclonal antibody and nano-microspheres. The kit comprises each 3 ml of four types of monoclonal antibody-polystyrene nano-microspheres PBS solution, 6 ml goat-anti-human polyclonal antibody and PBS solution, wherein the four types of the monoclonal antibody-polystyrene nano-microspheres PBS solution are sealed by bovine serum albumin and are respectively connected with a monoclonal antibody SZ-2, a monoclonal antibody SZ-22, a monoclonal antibody SZ-21, a monoclonal antibody 7E3, and the concentration of polystyrene nano-microspheres is 2 mg / ml; the goat-anti-human polyclonal antibody is connected with fluorescein isothiocyanate and with the concentration of the goat-anti-human polyclonal antibody is 15 mug / ml. A detection process of the specificity platelet antoantibody comprises the following steps of: oscillating monoclonal antibody--microspheres and platelet lysis buffer sample for incubation; washing by PBS; adding the goat-anti-human polyclonal antibody connected with the fluorescein isothiocyanate; washing, re-suspending by the PBS; detecting on a flow cytometry to obtain average fluorescence intensity values of the four types of the nano-microspheres respectively; and confirming whether the specificity platelet antoantibody is positive or not according to a ratio of the obtained values to a basic contrast value of that of a healthy person, in order to provide foundation for early diagnosis of ITP. The detection has the advantages of simple process, high sensitivity and good specificity.